Andrew has a background in Health Economics and Market Access, including roles in Policy Research and Market Access Consulting.

Most recently, he was a Managing Consultant with the Market Access Consulting team at Evidera, with responsibility for global pricing and market access strategies and value communication materials for new medicines. Andrew has worked across a wide range of disease areas and product types, including pharmaceuticals, medical devices and diagnostics. He has completed over 100 HEOR/market access projects, spanning commercial due diligence, global pricing strategies (including reference pricing), clinical/economic evidence development plans, HTA submissions and payer value communication resource development.

Andrew obtained his MSc Health Economics from the University of York, and has led a policy review at the Nova School of Business and Economics, Lisbon, regarding European Commission incentives for the development of orphan drugs.

‍

“I am committed to supporting the development of healthcare innovation with rapid access to strategic insight”